CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $31.00 target price on the stock.

A number of other research firms have also recently weighed in on CRVO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of CervoMed in a research report on Thursday, December 18th. Brookline Capital Acquisition raised CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Zacks Research raised CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Cantor Fitzgerald assumed coverage on CervoMed in a research note on Thursday, December 18th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.17.

CervoMed Trading Up 8.6%

CRVO stock opened at $4.93 on Wednesday. The firm has a 50-day moving average price of $6.74 and a 200-day moving average price of $7.93. CervoMed has a 12 month low of $1.92 and a 12 month high of $16.94. The stock has a market capitalization of $45.60 million, a P/E ratio of -1.70 and a beta of -0.82.

Institutional Trading of CervoMed

Several institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in CervoMed during the 1st quarter valued at approximately $227,000. Rhumbline Advisers boosted its stake in shares of CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the last quarter. Thompson Davis & CO. Inc. acquired a new stake in shares of CervoMed during the second quarter worth $91,000. Marshall Wace LLP bought a new position in CervoMed during the second quarter worth $76,000. Finally, Jane Street Group LLC acquired a new position in CervoMed in the second quarter valued at $414,000. 25.15% of the stock is currently owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.